Seres Therapeutics Inc's Customers Performance

Name: Seres Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

MCRB

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


MCRB's Source of Revenues		During the corresponding time, Seres Therapeutics Inc sequentially revenue grew by 105.59 %. While revenue at the Seres Therapeutics Inc 's corporate clients • List of MCRB Customers

for the same period Seres Therapeutics Inc sequentially revenue grew by 105.59 %.

• List of MCRB Customers

Seres Therapeutics Inc's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Seres Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Seres Therapeutics Inc Contracts

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

Exploring the Therapeutic Potential of SER-155: Insights from Biomarker Data and Economic Challenges of Seres Therapeutics The landscape of post-transplant care has continuously evolved, with recent advancements focusing on enhancing immune recovery and reducing complications after allogeneic hematopoietic stem cell transplantation (alloHSCT). Seres Therapeutics has made significant contributions in this area by exploring microbiome therapeutics to support favorable clinical outcomes. This article delves into the recent findings presented by Seres Therapeutics at the 2025 ASCO Annual Meeting concerning their investigational drug, SER-155, while also reflecting on the challenging financial landscape the comp...

SER-155 Shows Promise in Reducing Infection Rates and Antibiotic Use Post-Allogeneic Hematopoietic Stem Cell Transpla...

Seres Therapeutics has reported promising findings from its Phase 1b placebo-controlled trial evaluating SER-155 in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study demonstrated that SER-155 administration was significantly associated with a reduction in bacterial bloodstream infections (BSIs), systemic antibiotic exposure, and febrile neutropenia incidence compared to placebo through day 100 post-transplant.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a pivotal treatment for various hematological malignancies. However, it is frequently accompanied by severe complications, including infections, due to the immunocompromised state of patients. ...

Seres Therapeutics Secures $175M Lifeline through Nestlé Health Science Partnership Amid Plummeting Revenues...

Seres Therapeutics, a pioneering biotechnology company focused on developing microbiome therapeutics, has recently announced a significant financial move through an asset purchase agreement with Nestlé Health Science. This strategic deal, valued at $175 million, marks a crucial juncture for Seres amidst a notable revenue downturn. This article delves into the facets of the agreement and evaluates its potential implications for the company. The Agreement: On the 4th of October, Seres Therapeutics officially declared the signing of the VOWST Asset Purchase Agreement with Nestlé Health Science. The agreement outlines a significant cash infusion for Seres, which includes:- An upfront payment- Prepayment of a f...

MCRB's Stock Performance relative to it's Customers

MCRB's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Seres Therapeutics Inc	39.57	1.88	-22.46	66
SUBTOTAL	0.00	0.00	0.00	-

Sources: Seres Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Seres Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Seres Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.